Aprea Therapeutics
APRE
40 hedge funds and large institutions have $4.5M invested in Aprea Therapeutics in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 9 closing their positions.
4,709% more call options, than puts
Call options by funds: $1.11M | Put options by funds: $23K
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
0.29% less ownership
Funds ownership: 0.84% → 0.55% (-0.29%)
2% less funds holding
Funds holding: 41 → 40 (-1)
53% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 15
57% less capital invested
Capital invested by funds: $10.4M → $4.5M (-$5.86M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Crestline Management
Fort Worth,
Texas
|
+$101K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$93.4K |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$42.2K |
| 4 |
GTCM
Gyon Technologies Capital Management
Denville,
New Jersey
|
+$42.2K |
| 5 |
Two Sigma Investments
New York
|
+$38.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$1.25M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$699K |
| 3 |
JP Morgan Chase
New York
|
-$339K |
| 4 |
PP
PDT Partners
New York
|
-$232K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$177K |
APRE Hedge Fund Activity: Q1 2022 in Review
40 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q1 2022, worth a combined $4.5M — down 57% from $10.4M a quarter earlier.
Fund positioning in APRE was balanced in Q1 2022: 9 funds opened new positions, 9 closed out, 7 added to existing stakes and 15 trimmed.
The largest buyer was Crestline Management, opening a new position worth an estimated $101K. The largest seller was Pura Vida Investments, exiting entirely with an estimated $1.25M sold.
- 40 institutional investors held Aprea Therapeutics (APRE) as of Q1 2022, down from 41 in Q4 2021.
- Funds reported $4.5M of Aprea Therapeutics stock for Q1 2022, down 57% quarter-over-quarter.
- 9 funds opened new Aprea Therapeutics positions in Q1 2022 and 9 closed out, a net change of 0 holders.
- The largest Aprea Therapeutics buyer in Q1 2022 was Crestline Management, an estimated $101K added.
- The largest Aprea Therapeutics seller in Q1 2022 was Pura Vida Investments, an estimated $1.25M sold.
Based on aggregated 13F filings for Q1 2022.